305 related articles for article (PubMed ID: 35498998)
1. A comprehensive review on the glucoregulatory properties of food-derived bioactive peptides.
Jahandideh F; Bourque SL; Wu J
Food Chem X; 2022 Mar; 13():100222. PubMed ID: 35498998
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
3. Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Kato E
Biosci Biotechnol Biochem; 2019 Jun; 83(6):975-985. PubMed ID: 30773997
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in understanding the anti-diabetic actions of dietary flavonoids.
Babu PV; Liu D; Gilbert ER
J Nutr Biochem; 2013 Nov; 24(11):1777-89. PubMed ID: 24029069
[TBL] [Abstract][Full Text] [Related]
5. Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals.
Wang Y; Cai F; Li G; Tao Y
Bioengineered; 2022 Apr; 13(4):9184-9196. PubMed ID: 35383532
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
7. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
Lu Y; Lu P; Wang Y; Fang X; Wu J; Wang X
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646613
[TBL] [Abstract][Full Text] [Related]
8. Enhancing incretin action for the treatment of type 2 diabetes.
Drucker DJ
Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
10. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
Power O; Nongonierma AB; Jakeman P; FitzGerald RJ
Proc Nutr Soc; 2014 Feb; 73(1):34-46. PubMed ID: 24131508
[TBL] [Abstract][Full Text] [Related]
11. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
14. Kutkin, iridoid glycosides enriched fraction of Picrorrhiza kurroa promotes insulin sensitivity and enhances glucose uptake by activating PI3K/Akt signaling in 3T3-L1 adipocytes.
Sinha K; Kumar S; Rawat B; Singh R; Purohit R; Kumar D; Padwad Y
Phytomedicine; 2022 Aug; 103():154204. PubMed ID: 35671635
[TBL] [Abstract][Full Text] [Related]
15. Soy β-conglycinin improves glucose uptake in skeletal muscle and ameliorates hepatic insulin resistance in Goto-Kakizaki rats.
Tachibana N; Yamashita Y; Nagata M; Wanezaki S; Ashida H; Horio F; Kohno M
Nutr Res; 2014 Feb; 34(2):160-7. PubMed ID: 24461318
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
18. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
19. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.
Aroor AR; McKarns S; Demarco VG; Jia G; Sowers JR
Metabolism; 2013 Nov; 62(11):1543-52. PubMed ID: 23932846
[TBL] [Abstract][Full Text] [Related]
20. Bioactive Peptides as Potential Nutraceuticals for Diabetes Therapy: A Comprehensive Review.
Antony P; Vijayan R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
